Carbamate prodrug concept for hydroxamate HDAC inhibitors (Q30318440)

17 June 2017

Carbamate prodrug concept for hydroxamate HDAC inhibitors (English)

1 reference

17 June 2017

Saverio Cellamare

7

0 references

Manfred Jung

Manfred Jung

10

0 references

Wolfgang Sippl

Wolfgang Sippl

11

0 references

Lucia Altucci

Lucia Altucci

9

0 references

Vincenzo Carafa

Vincenzo Carafa

3

0 references

Diana A Stolfa

6

Diana A Stolfa

1 reference

17 June 2017

8

Angelo Carotti

1 reference

17 June 2017

Sonja Schlimme

1

1 reference

17 June 2017

Alexander-Thomas Hauser

2

1 reference

17 June 2017

Ralf Heinke

4

1 reference

17 June 2017

Srinivasaraghavan Kannan

5

1 reference

17 June 2017

17 March 2011

1 reference

17 June 2017

1 reference

17 June 2017

6

1 reference

17 June 2017

7

1 reference

17 June 2017

1193-1198

1 reference

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

17 June 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Chromatin modifications as targets for new anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Epigenetics--an epicenter of gene regulation: histones and histone-modifying enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

The human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

HDAC6 is a microtubule-associated deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecular Substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Histone deacetylase inhibitors: from bench to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Subtype selective substrates for histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

A non-isotopic assay for histone deacetylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

A homogeneous nonisotopic histone deacetylase activity assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100007

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CMDC.201100007

1 reference

17 June 2017

1 reference